Drugs / PR5I
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01839188 | May 2013 → Mar 2014 | meningococcal infection, viral infectious disease | MCM Vaccines B.V. | Completed | Met primary |
| Phase 3 | NCT01480258 | Nov 2011 → Oct 2013 | bacterial infectious disease, viral infectious disease | MCM Vaccines B.V. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PR5I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01480258 ↗ |
| Modality | Vaccine | “PR5I is a liquid suspension hexavalent vaccine.” NCT01480258 ↗ |
| Route | Intramuscular | “0.5 mL intramuscular injection” NCT01480258 ↗ |